Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
4.3K
Positive Regulator Molecules02:39

Positive Regulator Molecules

5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
Positive Regulator Molecules01:45

Positive Regulator Molecules

100.8K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
100.8K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

2.5K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same author

Breeding <i>Tm-1</i>-based tomato rootstocks, resistant to tomato brown rugose fruit virus, to impede soil-mediated viral infections.

Frontiers in plant science·2026
Same author

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.

Nature reviews. Drug discovery·2026
Same author

Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study.

JCO precision oncology·2026
Same author

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance.

bioRxiv : the preprint server for biology·2026
Same author

Minute amounts of helicase-deficient truncated RECQL4 are sufficient for DNA replication.

EMBO reports·2026

Related Experiment Video

Updated: Apr 26, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.3K

Cyclin E modulates vulnerability to CDC7 kinase inhibition.

Adam P Dommer1, Robert Kyne1, Jianxin Wang1

  • 1Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Oncogenesis
|April 24, 2026
PubMed
Summary

Triple-negative breast cancer (TNBC) cells with high cyclin E show increased sensitivity to CDC7 inhibition. Combining CDC7 and CDK8 inhibitors offers a potent therapeutic strategy, reducing tumor growth.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations
10:54

Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations

Published on: September 17, 2012

10.3K

Related Experiment Videos

Last Updated: Apr 26, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

10.9K
Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations
10:54

Studying Proteolysis of Cyclin B at the Single Cell Level in Whole Cell Populations

Published on: September 17, 2012

10.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • CCNE1 (cyclin E) amplification/overexpression is common in triple-negative breast cancer (TNBC).
  • Cyclin E overexpression causes replication stress and is linked to poor patient outcomes.
  • Targeting cyclin E-induced replication stress presents a therapeutic opportunity for TNBC.

Purpose of the Study:

  • To investigate the efficacy of CDC7 kinase inhibition in TNBC cells with CCNE1 overexpression.
  • To identify resistance mechanisms and synergistic targets for CDC7 inhibition in TNBC.

Main Methods:

  • Treatment of TNBC cells with CCNE1 overexpression using CDC7 inhibitors.
  • Assessment of cell proliferation, colony formation, and DNA content.
  • CRISPR screening to identify resistance genes.
  • Combination therapy with CDC7 and CDK8 inhibitors in vitro and in vivo.

Main Results:

  • CCNE1 overexpression sensitized TNBC cells to CDC7 inhibition, reducing proliferation and colony formation.
  • CDC7 inhibition caused replication timing delays and polyploidy (≥4N DNA content).
  • CDK8 was identified as a resistance factor to CDC7 inhibition; combined inhibition synergistically reduced proliferation and tumor growth.

Conclusions:

  • TNBC cells overexpressing cyclin E are uniquely vulnerable to CDC7 kinase inhibition.
  • Combined inhibition of CDC7 and CDK8 demonstrates significant therapeutic synergy against TNBC.
  • This combination therapy warrants further investigation for clinical application in TNBC treatment.